White Paper

Pharma R&D Annual Review 2022 Supplement: New Active Substances Launched During 2021

science drug development data iStock-1209661917

Following on from our review of trends in the current pharmaceutical R&D pipeline (download the report for free), this supplement takes a look at the industry’s success stories of 2021 – the drugs which were launched onto the market for the first time during the year. Our survey focuses exclusively on new active substances (NASs): new chemical or biological entities where the active ingredient had received no prior approval for human use. This would also include vaccines with novel antigenic components. As such, this list represents a subset of all the first launches which Pharmaprojects reported during 2021, and excludes an additional 75 first drug launches of reformulated or non-NAS moieties, biosimilars, and imaging agents. So, to continue with our travel-based theme this year, these are drugs which remembered their passports, tickets, and vaccine certificates, boarded the plane for their flight through clinical development, touched down safely, and have now successfully completed their journey and arrived at their chosen destination.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to:

Informa Pharma Intelligence